Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United States
2024

Effectiveness of the 2023–2024 Omicron XBB.1.5 COVID-19 Vaccine

Sample size: 1718670 publication 10 minutes Evidence: high

Author Information

Author(s): Kopel Hagit, Araujo Andre B, Bogdanov Alina, Zeng Ni, Winer Isabelle, Winer-Jones Jessamine P, Lu Tianyi, Marks Morgan A, Bonafede Machaon, Nguyen Van Hung, Martin David, Mansi James A

Primary Institution: Moderna, Inc.

Hypothesis

How effective is the mRNA-1273.815 vaccine in preventing COVID-19-related hospitalizations and medical encounters among adults?

Conclusion

The mRNA-1273.815 vaccine significantly protects against COVID-19-related hospitalizations and medically attended COVID-19 in adults.

Supporting Evidence

  • Vaccine effectiveness against COVID-19-related hospitalizations was 60.2%.
  • Vaccine effectiveness against medically attended COVID-19 was 33.1%.
  • Results were consistent across subpopulations, including older adults and those with underlying conditions.

Takeaway

The new COVID-19 vaccine helps keep people out of the hospital and reduces doctor visits for COVID-19.

Methodology

A retrospective cohort study using linked electronic health record and claims data to compare vaccinated and unvaccinated adults.

Potential Biases

Potential residual confounding may exist due to unmeasured characteristics.

Limitations

The study may not be generalizable to uninsured individuals and is subject to selection bias due to its nonrandomized nature.

Participant Demographics

Mean age was 63 years; 57% were female, and over 60% had underlying medical conditions.

Statistical Information

Confidence Interval

53.4–66.0

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/ofid/ofae695

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication